Tuberculosis and Beta-Lactam Antibiotics

Abstract

Tuberculosis (TB) is one of the oldest health problems in the world and it remains unresolved. Multidrug-resistant-TB and extensively resistant-TB are a serious problem for control programs. The evaluation of available antibiotics has gained importance in recent years for the treatment of resistant TB. Beta-lactam antibiotics inhibit cell wall biosynthesis in the bacteria; the presence of beta-lactamase enzyme in TB bacilli raises the question of whether this group of antibiotics can be used in treatment. As a result, it has been reported that the combination of beta-lactam antibiotics with beta-lactamase is effective against Mycobacterium tuberculosis both in vitro and in vivo. The aim of this article is to review and discuss up-to-date knowledge and future perspective on beta-lactam antibiotics and TB.

Mass spectrometry reveals potential of β-lactams as SARS-CoV-2 Mpro inhibitors

“…b-Lactam antibiotics form stable acyl-enzyme complexes with bacterial nucleophilic serine enzymes; they inhibit other nucleophilic serine enzymes including proteases and b-lactamases 16 and nucleophilic cysteine enzymes. 17 Studies on cephalosporins identified as potential inhibitors from the screen revealed no substantial covalent M pro modification, We further investigated b-lactam reactions with M pro using a diverse set of b-lactams (Fig. S17, ESI †).…”

Repurposing β-Lactams for the Treatment of Mycobacterium kansasii Infections: An In Vitro Study

“…In recent years, thanks to these approaches, β-lactams have regained importance in the treatment of several mycobacterial species. Amoxicillin plus clavulanate and meropenem plus amoxicillinclavulanate have been used against multidrug-resistant M. tuberculosis infections [10,33]. Moreover, amoxicillin-clavulanate is actually in clinical trials for the treatment of Buruli ulcer caused by M. ulcerans [34] and cefoxitin and imipenem are included in guideline recommendations in the treatment of M. abscessus [14,35].…”

Breaking barriers: The potential of nanosystems in antituberculosis therapy

“…MTB introduces a heightened challenge in TB therapy, stemming from its intrinsic ability to produce beta-lactamases [ 29 ]. Regarding these enzymes, Rv2068c (BlaC) stands out as a notable class A Ambler beta-lactamase due to its wide spectrum and resistance to clavulanate [ 30 ].…”

“…Furthermore, MTB possesses sophisticated defense systems that bolster its survival odds. Prominent among these are efflux pumps—protein structures nestled in the cell membrane essential for both the bacterium's physiological functions and its antimicrobial resistance [ 34 ]. Coupled with the bacterial permeability barrier, these pumps decrease the influx of antimicrobial agents into the external cell membrane while aiding drug expulsion.…”